Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Einstein-intervention testosterone replacement in testicular cancer survivors with mild Leydig cell insufficiency
2015-001452-30Phase 2Completed
- Sponsor
- Copenhagen University Hospital Rigshospitalet
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Hypoandrogenism (TD), Leydig cell hypoplasia (LCH) and cardiometabolic risk (CMR) comparing Testosterone replacement (Tostran) with Placebo (2 arms). Primary endpoint: Insulin sensitivity. Started Sep 2015; status: completed.
02
Drugs
AndroForte
03
Conditions
Hypoandrogenism (TD)Leydig cell hypoplasia (LCH)cardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2015-001452-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001452-30.